CORONA Remedies Ltd. (CORONA) fundamentals
CORONA Remedies Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as CORONA (ISIN INE02ZQ01018). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What CORONA Remedies Ltd. does
Corona Remedies Limited is an India-based pharmaceutical formulation company. The Company is engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabetes, pain management, urology and other/multispecialty pharmaceuticals (comprising vitamins/minerals/nutrition (VMN), gastrointestinal and respiratory). Its diverse product portfolio comprises approximately 67 brands catering to a range of therapeutic areas. It has four dosage forms in pain management formulations, which it offers in the form of tablets, capsules, sprays and injections for treatments associated with musculoskeletal spasms and diabetes. It holds brands across the women’s healthcare lifecycle, from adolescence to infertility, pregnancy, post-pregnancy and pre- and post-menopause categories. Its brands include such as C-HOP; Trazer; COR; Cortel; Rosuless; Bisobis; Sitabite; Dapabite; Fur; Voglibite; Angiwell; Stimucor; Argihope, and others.
Valuation and market data
| Last close | ₹2236.10 |
|---|---|
| Market capitalisation | ₹13,675 crore |
| Enterprise value | ₹13,770 crore |
| P/E (TTM) | 73.87 |
| Price to book | 18.31 |
| Price to sales (TTM) | 5.39 |
| Book value per share | ₹122.12 |
| Dividend yield | 44.72% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Dec 15 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹1,414 crore | ₹240 crore | ₹185 crore | 30.22 |
| Mar 2025 | ₹1,202 crore | ₹198 crore | ₹149 crore | 24.37 |
| Mar 2024 | ₹1,021 crore | ₹118 crore | ₹91 crore | 14.80 |
| Mar 2023 | ₹891 crore | ₹111 crore | ₹85 crore | 14.53 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 69.0% |
|---|---|
| Foreign institutions (FII) | 3.6% |
| Mutual funds | 12.5% |
| Other domestic institutions | 0.4% |
| Retail and others | 14.5% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.